KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q3 2025 value amounting to -$2.7 billion.

  • Alnylam Pharmaceuticals' Enterprise Value rose 170.6% to -$2.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.7 billion, marking a year-over-year increase of 170.6%. This contributed to the annual value of -$2.7 billion for FY2024, which is 1053.11% down from last year.
  • Alnylam Pharmaceuticals' Enterprise Value amounted to -$2.7 billion in Q3 2025, which was up 170.6% from -$2.9 billion recorded in Q2 2025.
  • In the past 5 years, Alnylam Pharmaceuticals' Enterprise Value registered a high of -$1.7 billion during Q1 2021, and its lowest value of -$2.9 billion during Q2 2025.
  • Its 5-year average for Enterprise Value is -$2.3 billion, with a median of -$2.4 billion in 2024.
  • Examining YoY changes over the last 5 years, Alnylam Pharmaceuticals' Enterprise Value showed a top increase of 870.97% in 2022 and a maximum decrease of 3358.38% in 2022.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Enterprise Value stood at -$2.4 billion in 2021, then increased by 8.71% to -$2.2 billion in 2022, then dropped by 12.3% to -$2.4 billion in 2023, then dropped by 10.53% to -$2.7 billion in 2024, then dropped by 1.42% to -$2.7 billion in 2025.
  • Its last three reported values are -$2.7 billion in Q3 2025, -$2.9 billion for Q2 2025, and -$2.6 billion during Q1 2025.